Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

October 31, 2009

Conditions
UveitisPosterior UveitisPanuveitis
Interventions
DRUG

AEB071

Trial Locations (13)

10003

New York Eye and Ear Infirmary, Clinical Research Department, New York

21287

John Hopkins Hospital/Wilmer Eye Institute, Baltimore

30322

Emory University, Atlanta

33136

University of Miami Miller School of Medicine; Anne Bates Leach Eye Hosptial;Bascom Palmer Eye Institute, Miami

33612

University of South Florida, Eye Institute, Tampa

55905

Mayo Clinic Department of Opthalmology, Rochester

77030

Vitreoretinal Consultants, Houston

78705

Retina Research Centre, Austin

80230

Colorado Retina Associates, Denver

90033

University of Southern California Doheny Eye Institute, Los Angeles

94143

University of California, San Francisco

02142

MERSI, Cambridge

07666

Cornea and Laser Eye Institute, Teaneck

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00615693 - Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis | Biotech Hunter | Biotech Hunter